Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- Main trialPhase 1/2
- “This is a multi-center, open-label phase 1/2 trial evaluating the safety and efficacy of AB-2100 cell product. The study may enroll approximately 60 patients in phase 1 and approximately 70 patients in phase 2.”In the company’s words, NCT06245915 on ClinicalTrials.gov
- Other names
- Integrated Circuit T cells
Other drugs for Advanced/Metastatic Clear Cell Renal Cell Carcinoma
- CasdatifanArcus Biosciences · Phase 3
- EB-701/CA9-NKBeijing Biotech · Phase 1/2
- AxitinibPfizer · Phase 1/2
- PF-08634404Pfizer · 3SBio · Phase 1/2
- NEO-811Neomorph, Inc · Phase 1
- ALLO-316Allogene Therapeutics · Phase 1
Coming up1
- 31 DecPhase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Active, not recruiting | 31 Dec 2026 | AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026